BioSpace News Archive

Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), today announced financial results and recent corporate highlights for the second quarter and six months ended June 30, 2022.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced that its product portfolio of FDA-approved brands delivered combined revenues of $10.3 million during the second quarter of 2022 – a 14% increase over the prior year period.

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today reported financial results for the quarter and six months ended June 30, 2022. INOVIO’s management will host a live conference call and webcast at 4:30 p.m. Eastern Daylight Time (EDT) today to discuss financial results and provide a general business update for the second quarter.

Agiliti Inc., a nationwide provider of healthcare technology management and service solutions to the United States healthcare industry, announced its financial results for the quarter ended June 30, 2022, and reaffirmed its full-year financial guidance with results expected at the lower end of its range.

Highlights for Second Quarter 2022: Record revenues of $23.3 million, up 29% over $18.1 million for the prior‑year quarter Record gross profit of $16.8 million, up 22% over $13.7 million for the prior‑year quarter A record 718,000 product units shipped, up 4% from the prior-year quarter Cash and cash equivalents of $46.4 million as of June 30, 2022

Arcturus Therapeutics Holdings Inc., a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced its financial results for the second quarter ended June 30, 2022, and provided corporate updates.

Omeros Corporation (Nasdaq: OMER), today announced recent highlights and developments as well as financial results for the second quarter.

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced financial results for the second quarter ended June 30, 2022, and provided a corporate update.

The latest market analysis report published by Reports and Data, titled ‘Global Dysthymia Market – Forecast to 2030,’ thoroughly examines the Dysthymia industry to provide essential data & information for the targeted readers.

Today InsightRX, a high-growth healthcare technology company that provides cloud-based clinical decision support for point-of-care precision dosing, announced its partnership with Healix, the national leader in physician office-based infusion services.